Tekton Research

1. Pfizer Inc. $4,499,928 307 payments
2. Moderna TX, Inc. $2,649,210 156 payments
3. AstraZeneca UK Limited $1,235,778 12 payments
4. AstraZeneca Pharmaceuticals LP $1,065,579 20 payments
5. GlaxoSmithKline, LLC. $881,417 243 payments
6. AbbVie, Inc. $671,019 281 payments
7. Valneva Austria GmbH $460,566 15 payments
8. Boehringer Ingelheim Pharmaceuticals, Inc. $459,849 14 payments
9. Novartis Pharmaceuticals Corporation $338,395 6 payments
10. E.R. Squibb & Sons, L.L.C. $257,274 15 payments

1. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $2,666,254 263 payments
2. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Adults 60 Years of Age $2,348,182 108 payments
3. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $1,778,523 22 payments
4. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $1,104,048 6 payments
5. A Phase I/II, Double-blinded, Randomized, Placebo-Controlled, Dose Selection Study in Adults to Assess the Safety and Immunogenicity of AZD4117 and AZD5315 Vaccines PANDA $488,649 2 payments
6. Obesity Long term safety in patients with CV risk $486,578 11 payments
7. A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study to Evaluate Safety and Immunogenicity of A Live-Atteuated Chikungunya Virus Vaccine Candidate (Vla1553) in Adults Aged 18 Years and Above $460,566 15 payments
8. A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19 $424,893 4 payments
9. A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $368,658 86 payments
10. A Randomized Double Blind Placebo Controlled Phase III Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 16 Weeks and to Assess the Long Term Efficacy Safety and Tolerability Up to 52 Weeks in Patients With $335,592 3 payments

1. Patient care $107,092 31 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.